These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9789708)

  • 41. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril.
    Kalinyak CM
    Int J Psychiatr Nurs Res; 1998 Sep; 4(2):445-51. PubMed ID: 10451301
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
    Friedman JH; Berman RM; Goetz CG; Factor SA; Ondo WG; Wojcieszek J; Carson WH; Marcus RN
    Mov Disord; 2006 Dec; 21(12):2078-81. PubMed ID: 17013906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clozapine prevents recurrence of psychosis in Parkinson's disease.
    Factor SA; Brown D
    Mov Disord; 1992; 7(2):125-31. PubMed ID: 1350059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Olanzapine as an alternative in clozapine-induced akathisia?].
    Knoch H; Hofmann M; Seifritz E
    Psychiatr Prax; 1999 Nov; 26(6):308. PubMed ID: 10627963
    [No Abstract]   [Full Text] [Related]  

  • 46. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study.
    Meco G; Alessandri A; Giustini P; Bonifati V
    Mov Disord; 1997 Jul; 12(4):610-2. PubMed ID: 9251085
    [No Abstract]   [Full Text] [Related]  

  • 48. An open trial of olanzapine in patients with treatment-refractory psychoses.
    Sanders RD; Mossman D
    J Clin Psychopharmacol; 1999 Feb; 19(1):62-6. PubMed ID: 9934945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients.
    Wagner ML; Defilippi JL; Menza MA; Sage JI
    J Neuropsychiatry Clin Neurosci; 1996; 8(3):276-80. PubMed ID: 8854298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.
    Rudolf J; Grond M; Neveling M; Heiss WD
    J Neural Transm (Vienna); 1997; 104(11-12):1305-11. PubMed ID: 9503276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.
    Frieling H; Hillemacher T; Ziegenbein M; Neundörfer B; Bleich S
    Eur Neuropsychopharmacol; 2007 Feb; 17(3):165-71. PubMed ID: 17070675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine.
    Meltzer HY; Kennedy J; Dai J; Parsa M; Riley D
    Neuropsychopharmacology; 1995 Feb; 12(1):39-45. PubMed ID: 7766285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clozapine as a treatment for psychosis in Parkinson's disease: a review.
    Musser WS; Akil M
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):1-9. PubMed ID: 8845691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clozapine in the treatment of psychosis in Parkinson's disease.
    Friedman JH; Lannon MC
    Neurology; 1989 Sep; 39(9):1219-21. PubMed ID: 2771073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antipsychotic agents and bipolar disorder.
    Tohen M; Zarate CA
    J Clin Psychiatry; 1998; 59 Suppl 1():38-48; discussion 49. PubMed ID: 9448668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.
    Onofrj M; Thomas A; Bonanni L; Iacono D; Gambi F
    Neurol Sci; 2000 Aug; 21(4):209-15. PubMed ID: 11214659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic management of psychosis in the elderly: a critical review.
    Hoeh N; Gyulai L; Weintraub D; Streim J
    J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):213-8. PubMed ID: 14653429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychosis in Parkinson's disease: therapeutic options.
    Hasnain M
    Drugs Today (Barc); 2011 May; 47(5):353-67. PubMed ID: 22013566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
    Rudolf J; Ghaemi M; Schmülling S
    Eur Psychiatry; 1999 Oct; 14(6):356-7. PubMed ID: 10572371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.
    Scholz E; Dichgans J
    Eur Arch Psychiatry Neurol Sci; 1985; 235(1):60-4. PubMed ID: 2864254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.